Depth bar: Band A employee-heavy / revenue-soft account. Public financials thin — every scrap listed + explicit gap list. Estimates [~]; directory phones [dir]. Do not invent HT bill figures. Qualify ≥ ₹30 lakh/month before standard Band A fee; else Path B.

1. Company overview & snapshot

1.1 Legal identity & corporate structure

Eskag Pharma Private Limited (also styled Eskag Pharma Pvt. Ltd. / ESKAG Pharma (P) Ltd.) is a private unlisted Indian company incorporated 24 February 1977, CIN U24234WB1977PTC030897, ROC Kolkata. Registered / corporate address (imprint and MCA-style records): AG-112, Unit No. 4 / Suite 804 & 805, 8th Floor, Baisakhi, Sector-II, Salt Lake (Bidhannagar), Kolkata, West Bengal 700091. Authorised capital ~₹1.80 Cr; paid-up ~₹1.68 Cr [dir/aggregator].

Board / promoters (company imprint pages):

• Sunil Kumar Agarwal — Chairman & Managing Director
• Anil Kumar Agarwal — Director
• Sashreek Agarwal — Director (listed on eskag.in imprint)

PAN cited on imprint: AAACE5646H (state GST variants below). Open charges on CompanyCheck-type aggregators (~₹127 Cr open charges cited) should be re-verified on MCA before any credit conversation — do not use as outreach talking points.

Group context: Eskag markets itself as part of a broader Eskag Group including formulation brands, West Bengal Chemical Industries Ltd (WBCIL) (API/intermediates SBU in group narratives), and Eskag Sanjeevani Multispecialty Hospital. Employee “4,500 staff / 5,00,000+ sq.ft” claims appear in group promotional interviews — treat as group-level marketing, not Eskag Pharma Pvt Ltd headcount. For Stamped, the legal and bill entity is Eskag Pharma Private Limited Haridwar manufacturing units unless the HT bill says otherwise.

GST / tax: Corporate imprint lists PAN 19AAACE5646H1ZJ framing; Uttarakhand manufacturing GST commonly referenced in directories as 05AAACE5646H1ZS [dir] — confirm on the physical UPCL invoice / GST portal before CRM write-up.

1.2 What they make & where money comes from

Eskag positions as a WHO-GMP third-party / contract manufacturing plus branded formulations house with 50+ years of industry narrative (founding lore often cites 1972 group start vs 1977 company incorporation — note the discrepancy).

Dosage forms & categories (company sites):

• Tablets, capsules, syrups/suspensions, powders, creams/gels/ointments
• Select injectables
• Hormonal and non-hormonal segregation marketed heavily
• Nutraceuticals / cosmeceuticals on third-party pages
• Therapeutic emphasis: gastroenterology (antacids, anti-ulcerants, sucralfate), probiotics/prebiotics, ORS/antidiarrhoeals, haematology/haematinics, gynaecology / oral contraceptives (flagship brand narratives around Suvida OCP), osteo, dermatology, pediatrics

Scale signals:

Money motion: Mix of own brands (institutional/retail India) + contract manufacturing for Indian and MNC partners + government/tender channel (LinkedIn technical-head profiles describe GeM / state corporation tendering). For energy economics, multi-SKU / multi-dosage campaigning creates the HVAC attribution problem Stamped sells against.

1.3 Plants, addresses & footprint

Contact phones: Corporate +91 33 40251500 / email eskag@eskag.in (verified imprint). Haridwar landline 01334-239429 [dir].

Pilot recommendation: Treat Plots 31–34 as one SIDCUL campus but start with one UPCL HT consumer account (likely one plot is the billed premises — discover which). Do not invent a multi-meter campus without invoices. Preferred first technical scope: hormonal + injectable/HVAC cluster on the fattest bill.

1.4 Leadership & CRM map

Buying-path risk (material): Kolkata HQ owns budget; Haridwar executes. Lead report flags this. Sequence: plant engineering credibility → Plant Head → CMD WhatsApp/email with a one-page ₹ opportunity after bill view, not a SaaS demo. Decision speed may be slower than owner-operated single-site SMEs.

1.5 Recent news (24 months) & timing for Stamped

• Marketing refresh of third-party / export positioning on eskag.co.in / eskag.in (WHO-GMP, 500+ formulations).
• Group affordability / CSR awareness campaigns (Dailyhunt-style features via WBCIL/group channels) — use only as brand context, not energy proof.
• MCA AGM markers on aggregators into Sep 2025 with balance sheet 31 Mar 2025 — company active.
• No major 2024–26 M&A headline found for Eskag Pharma Pvt Ltd itself.
• Profitability / EBITDA compression signals (aggregator) → cost narrative should work if bill clears threshold; if bill is thin, Path B only.

Timing: Good for a plant-first technical conversation during utilisation pushes; poor if a major WHO/customer audit week locks SOPs. Ask for audit calendar.

2. Energy profile

DISCOM / supply (name early): UPCL for Haridwar SIDCUL HT industrial connections. Confirm consumer name Eskag Pharma Pvt Ltd / Unit I–IV on the invoice header.

2.1 Bill band, tariff & demand

No public bill. Working hypothesis for a 4-plot, multi-dosage (including hormonal + injectables) WHO-GMP campus with ~600 staff on-site-capable scale: monthly electricity ₹20–55 lakh [~], with a realistic chance of sitting near / below the ₹30L Band A hard floor. This is an estimate — the entire commercial motion depends on verification. If invoices show ≥ ₹30L, proceed Band A 90-day; if ₹15–29L with clear MD pain, Path B; if < ₹15L, nurture / skip.

Mandatory ask: sanctioned demand (kVA), recorded MD peaks last 12 months, ToD, PF, whether Units share one HT or multiple consumers, and CETP/common utilities electrification peculiarities if any.

2.2 Generation, fuel & renewables

Documented: UKPCB OCMMS inspection note for Eskag Pharma Pvt Ltd Unit I (inspection 18 Sep 2021) records a DG set of 125 kVA with acoustic enclosure and proper stack, in context of CCA-renewal. Lead report conversation starter intentionally uses this. Treat 125 kVA as verified historic consent-file equipment, not necessarily the only or current DG farm — ask for today’s DG inventory and runtime hours.

Boiler / thermic / steam presence for liquids/ointments is likely but not publicly inventoried. No public rooftop solar MW claim found in this research pass. CETP connection for effluent (Haridwar CETP) appears in UKPCB notes — environmental utility, not electrical, but signals process intensity.

2.3 EnMS, PAT, ISO, BRSR

• Company marketing: WHO-GMP, ISO 9001, HACCP for Haridwar facility.
• ISO 50001: not found in public claims reviewed.
• PAT / BRSR: private unlisted — no BRSR obligation; no PAT designate found.
• Implication: expect weaker formal EnMS than listed peers (Akums, Windlas). Stamped entry can be stronger (“first continuous bill-tied layer”) but data access may be Path B CSV + logbooks unless BMS exists for HVAC.

2.4 Likely ₹ leak categories (hypothesis)

1. Hormonal / segregated HVAC always-on between batches (top wedge).
2. Injectable / liquid suite cleanroom + sterilisation / CIP energy spikes coinciding with OSD packing starts → MD.
3. PW / WFI generation and recirculation pumps continuous operation (Sourish’s portfolio).
4. Compressed air for packing and process.
5. 125 kVA DG runtime vs tariff/outage habit — diesel cost + failed load management on grid MD.
6. Multi-plot diversity factor — if separately metered, wrong unit gets the first call; if single meter, attribution nightmare (Stamped opportunity).
7. Idle syrup/ointment utilities between SKUs (500+ SKU theatre).

3. Operations, equipment & digital stack

3.1 Process flow & critical loads

Across Units I–IV, expect parallel trains: solid orals (dispense → granulate/blend → compress/fill → coat/pack), liquids (compounding → filling → packing), semi-solids (cream/ointment), and restricted hormonal suites with dedicated AHUs/airlocks, plus select injectable trains with higher clean-utility intensity. Critical loads: HVAC/AHUs, chillers, PW/WFI, pure steam if present, compressors, vacuum, purified-water loops, packing lines, and DG backup.

UKPCB Unit-I note lists raw materials including divalproex sodium, sucralfate, PEG-4000 — consistent with neuro/GI liquid/solid mix; does not exhaust hormonal/injectable inventory on other plots.

3.2 Shifts, seasonality, production pattern

Likely multi-shift production with campaigning by SKU/customer. OCP / tender orders can create burst packing. Seasonal antidiarrhoeals/ORS may swing liquid lines. Changeovers on 500+ SKUs create idle-cleanroom inventory — best Stamped observation window. Normalise bills to batch counts / packing hours, not calendar days alone.

3.3 Automation, metering, SCADA/EMS/DCS

No public named DCS/EMS vendor for Eskag Haridwar found. Engineering function documents HVAC, PW/WFI, QMS — suggests utility equipment sophistication without proving a plant-wide energy management system. Assume Path B unless contradicted: HT interval data (if DISCOM provides), sub-meter logs if any, and production schedule from Plant Head. Electrical Maintenance Engineer presence implies LT panel / motor management capacity to execute sequencing prescriptions.

3.4 Capex / tech projects affecting energy

Plots 31–34 adjacency suggests staged expansion historically (CTE/CCA journey visible in older OCMMS notes from ~2018–2021). Any recent HVAC/chiller upgrades will alter baselines. Ask for capex register FY24–26 (AHU, chiller, compressor, DG, solar). Position Stamped as post-capex verification if they just spent.

4. Stamped Energy fit analysis

4.1 ICP scorecard

4.2 Fit score rationale

7/10: Process + multi-unit HVAC story strong; revenue and possible bill-floor miss are the deductions; HQ distance adds friction. Employee-heavy operations inflate onsite utility urgency relative to topline — good for Path B if Band A bill fails.

4.3 Wedge (parser-critical)

The strongest wedge is: on the Haridwar SIDCUL campus (Plots 31–34), tie hormonal/injectable HVAC and PW–WFI recirculation that stays live between campaigns — plus 125 kVA DG vs grid MD behaviour — to named ₹ lines on the UPCL bill, assign owners via WhatsApp, and verify one move in 90 days without hardware or PLC writes.

4.4 Objections & competitors

4.5 Pilot design

• Scope: One HT consumer on Sector 6A campus; focus HVAC + PW/WFI + compressor + DG runtime.
• Weeks 1–2: Bill pair, meter boundary, DG logbook, campaign calendar for hormonal vs general.
• Weeks 3–8: Prescriptions (AHU hold, recirculation, sequencing, PF, DG habit).
• Weeks 9–12: Invoice + production-normalised proof.
• Success / kill: Same Stamped standard; extra kill if Kolkata refuses any plant vendor without 6-month tender.

5. Before you reach out

5.1 Discovery checklist

• Confirm UPCL account legal name and which plot(s) it covers.
• Verify bill band (₹ lakh/month) and 12-month MD chart.
• Confirm GSTIN on bill vs 05-series UK registration.
• Ask: hormonal AHUs — dedicated meters or lump?
• Ask: injectable block operating hours vs HVAC hours.
• Ask: current DG kVA list + monthly runtime vs outage log.
• Ask: who in Kolkata signs a ₹2–5L (or Path B) pilot?
• Ask: any EMS/BMS already quoting?
• Request two bills + one week interval if available.
• Confirm Sourish/Balyan still in role week-of-send.
• Check CETP / UKPCB consent validity offline (not a pitch topic).
• Clarify email domain @eskag.in vs @eskag.co.in.

5.2 Do not lead with

• Do not lead with dashboards, AI, or carbon/ESG.
• Do not lead with Kolkata HQ brand stories or hospital/group CSR.
• Do not confuse Sujit Bose (govt tenders) with engineering.
• Do not state ₹50–100 Cr revenue or ₹20–55L bill as proven fact.
• Do not attack WHO-GMP practices; respect segregation rules.
• Avoid claiming “none of your competitors meter this” — Akums next door is sophisticated.

5.3 Opening hooks (email / call / WhatsApp)

“Across Plots 31–34, hormonal HVAC and PW loops often outrun the batch schedule while one UPCL MD line still fires — we sit read-only, put ₹ on each event, and check the next bill.” Ask: “Is grid MD or DG runtime the bigger monthly surprise?”

6. Risks, flags, controversies & sources

6.1 Integrity / controversy / regulatory (search explicitly)

Controversies / lawsuits / raids — result of explicit search

Search terms used (Jul 2026 research pass): Eskag Pharma lawsuit, Eskag Pharma fraud, Eskag Pharma NGT, Eskag Pharma UKPCB notice, Eskag Pharma labour dispute, Eskag Pharma ED, Eskag Pharma CBI, Eskag Pharma tax raid, Eskag Agarwal controversy, Eskag Pharma Haridwar pollution.

Result: no material adverse press hit tying Eskag Pharma Pvt Ltd to ED/CBI fraud, NGT parties, or major labour litigation in the open-web results reviewed. An NGT e-journal PDF that appeared in keyword search related to unrelated UPPCB parties, not Eskag — do not attach.

Regulatory / consent (routine, not scandal):

• UKPCB OCMMS inspection notes (Unit I 2021-09-18; campus notes 2021-01-16) describe CCA renewal mechanics, orange-category, CETP connectivity, fees paid, and 125 kVA DG presence. These are normal consent management, not enforcement crackdowns. Confirm whether CCA remains current into 2025–26 before site visits if environmental diligence is required by Stamped internal policy — but do not open sales with PCB history.

Initiatives / positives:

• Long-running WHO-GMP / ISO / HACCP marketing; export documentation posture.
• Group healthcare access / awareness campaigns (Suvida medical camps language in features).
• Active third-party manufacturing growth messaging and global market pages.

Commercial stress flags (not integrity):

• Revenue soft vs Band A; EBITDA volatility on aggregators; open-charge levels on MCA aggregators warrant finance caution if proposing credit terms (prefer prepaid 90-day).

6.2 Data quality flags

• Dual websites (eskag.in vs eskag.co.in) with slight unit-number swaps (Plot 31 vs 32 labelled Unit I/II differently across pages) — reconcile on visit.
• Employee counts conflict (122 LinkedIn vs 594–654 filings).
• Revenue only in bands.
• Bill unknown — highest commercial risk.
• Kolkata vs Haridwar authority ambiguity.
• Email inference only except eskag@eskag.in.
• Possible name collision with other “Eskag” group entities — keep CIN/GST tight.

6.3 Sources consulted

• https://www.eskag.co.in/ ; /contact/ ; /about-eskag/ ; /imprint/
• https://www.eskag.in/ ; /contact/ ; /about-us/ ; /imprint/ ; /third-party-manufacturing/
• UKOCMMS inspection notes (Unit I 125 kVA DG; CETP; CCA renewal narrative)
• Tracxn / CompanyCheck / Economic Times company snapshot pages
• LinkedIn company + Sourish Sar, Sunil Balyan, Kunal Dey Sarkar, Sujit Kumar Bose
• WBCIL/Dailyhunt group feature PDF (soft brand context only)
• Lead report Lead 17: leads/uttarakhand/lead-research-uk-gap-verticals-2026-07.md
• Master index entries 16–17 context; ICP v2; Stamped messaging canon
• Peer kits tone: outreach/2026-07-pb-up-uk-gap/10-akums-drugs.md

Extended call-prep narrative (Stamped field use)

B1. First 20 minutes of discovery

Open with process respect, not software. Confirm legal entity on the invoice, DISCOM name, and who owns the largest feeder MD event in the last 90 days. Ask for two invoices and one production calendar export before any platform demo. If the champion cannot produce bills within a week, treat the opportunity as stalled — Bill Verification Program without invoices is theatre. Record whether Path A (historian/meter export) or Path B (CSV) is realistic given OT policy. Confirm the economic buyer who can approve a Rs 2–5 lakh [~] fixed 90-day fee without a full ERP tender.

B2. Prescription card discipline

Every recommendation must name: event, owner, due date, expected rupee line on the DISCOM invoice, operational constraint, and evidence of execution. Cards without owners are deleted. Cap weekly cards at five so plant teams are not flooded. Prefer MD sequencing and idle-hold cuts before exotic tariff products. Never propose changing validated recipe, membrane current, sterile pressure, or Tempcore quench parameters. If quality or safety forbids a schedule change, mark the lever as blocked and move on — credibility beats aggressive savings claims.

B3. Verifying savings without gaming

A lower bill alone is not success if tonnes, pairs, or batches fell. Normalise against a production proxy agreed in week 1. Document holidays, forced outages, new-line commissioning, captive/solar settlement changes, and weather-sensitive HVAC. Keep a decision ledger shared with the plant: recommendation, owner, status, expected vs observed invoice delta. Present kill or expand at day 90 with the same ledger — this is how Stamped differs from audit PDFs that never close.

B4. Competitive and incumbent handling

If the site has EMS/SCADA/BMS, OEM analytics, ISO consultants, or solar EPCs, congratulate the spend and ask what residual bill lines still surprise them monthly. Position Stamped as the closure layer: rupee assignments and invoice reconciliation. Refuse head-to-head dashboard bake-offs. If Gujarat, Panipat, or Noida corporate IT appears, keep plant electrical as the proof owner and let corporate rubber-stamp after a verified bill line — not before.

B5. Geographic and cluster logistics

Batch 3 spans Mandi Gobindgarh, Paonta/Derabassi/Rajpura, Ghaziabad/Muzaffarnagar, and Kanpur–Unnao. Plan field days by corridor. Carry printed one-pagers: Fit score, DISCOM hypothesis, strongest wedge sentence, and two discovery questions. After each visit, update extras field intel — especially corrected phones, electrical names, and whether the bill cleared Rs 30 lakh/month.

B6. Messaging hygiene for this batch

Owner-operated steel/leather accounts tolerate Hindi-friendly WhatsApp and short calls. Listed pharma/chemical accounts prefer email plus LinkedIn with technical depth. Never open with controversies (GST/Excise history, EuGMP observations, rating actions) — those are internal briefings only. Always name DISCOM early in research-backed prep sheets so call-prep UI can render correctly.

6.4 Evidence discipline and next research actions

1. Pull two UPCL bills before any ROI model.
2. MCA charge extract if commercial credit is debated.
3. Confirm Unit map with gate photos / consent files.
4. Re-check LinkedIn titles week-of-send (Sourish role dated Jun 2025 — new enough to confirm).
5. If bill ≥ ₹30L, draft Path A; else Path B one-pager for CMD.
6. Do not expand to WBCIL API plants without separate qualification.

6.5 Explicit information gaps

1. Exact FY25 audited revenue and power & fuel line.
2. Monthly UPCL ₹ and kVA MD.
3. Which plot holds which HT consumer number(s).
4. Current DG inventory beyond historic 125 kVA Unit I.
5. Named BMS/chiller OEM.
6. Verified personal emails for Sourish / Balyan.
7. Whether Kolkata still runs any formulation HT load.
8. Customer audit calendar H2 2026.
9. Live CCA validity dates 2025–26.
10. Any private EMS tender already floated.
11. Exact hormonal block footprint (AHU count).
12. Captive solar / open access contracts if any.

6.6 Operating narrative for the call (synthesis)

Eskag is a classic North India SIDCUL pharma mid-market account: process-rich, disclosure-poor, HQ-distant. The Stamped story is not “you’re an energy laggard”; it is “multi-SKU hormonal + injectable utilities create bill opacity that monthly kWh totals cannot resolve.” Success depends on bill-floor honesty and a Kolkata economic buyer who likes kill-criteria pilots. Neighboring Akums/Themis sophistication raises the bar for language quality — never sound like a hardware vendor.

If discovery shows a single soft bill, still capture MD sequencing pain for Path B or a multi-site Eskag group expansion later. If discovery shows ≥ ₹30L with four-plot HVAC complexity, escalate this account inside UK Pharma cluster as a proof twin to larger CDMOs for “private mid-market” messaging.

Agent note: Thin public financials are filled by expanding process, UKPCB, CRM, and buying-path analysis rather than fabricating numbers. Gap list above is mandatory reading before the first call.